<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01448265</url>
  </required_header>
  <id_info>
    <org_study_id>CRYO-MAP</org_study_id>
    <nct_id>NCT01448265</nct_id>
  </id_info>
  <brief_title>Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter</brief_title>
  <acronym>CRYO-MAP</acronym>
  <official_title>Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Atrial fibrillation (AF) is the most frequent sustained cardiac arrhythmia,&#xD;
      impairs quality of life and increases stroke risk and mortality. Recent clinical experience&#xD;
      with the Arctic Front™ cryoballoon ablation catheter system (Medtronic) suggests that it can&#xD;
      be used to isolate the pulmonary veins (PVs) safely and effectively in patients with AF,&#xD;
      thereby eliminating the recurrence of AF.&#xD;
&#xD;
      Hypothesis: Our hypotheses are (1) that visualization of real-time pulmonary vein conduction&#xD;
      during cryoballoon ablation of atrial fibrillation using a novel spiral circumferential&#xD;
      mapping catheter (Achieve™) is feasible and safe, and (2) that procedure and fluoroscopy&#xD;
      times decrease with experience.&#xD;
&#xD;
      Objective: The purpose of this study is to assess safety, feasibility, and a learning curve&#xD;
      associated with cryoballoon catheter ablation using a novel circular mapping catheter&#xD;
      (Achieve™, Medtronic) inserted through the lumen of the cryoballoon in patients with&#xD;
      symptomatic paroxysmal atrial fibrillation.&#xD;
&#xD;
      The primary goal is to evaluate successful pulmonary vein isolation using the Achieve™&#xD;
      mapping catheter. The reduction of procedure and fluoroscopy times during the first 40&#xD;
      patients treated with this approach will be analyzed to evaluate a potential learning curve&#xD;
      upon introduction of the technique.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 40 patients scheduled for a first ablation of paroxysmal AF will be included. All&#xD;
      study subjects will undergo cryoablation using the 28 mm Arctic Front™ Cryoablation Catheter.&#xD;
      A double transseptal approach will be followed in all study patients, allowing for use of&#xD;
      regular guide wire and circular mapping catheter, respectively, if required.&#xD;
&#xD;
      Use of the 20 mm Achieve™ circular mapping catheter is preferred. The 15 mm AchieveTM&#xD;
      catheter may be used at the physician's discretion. If stable balloon positions cannot be&#xD;
      obtained, the Achieve™ catheter will be replaced by a regular guide wire and pulmonary vein&#xD;
      isolation will be assessed by a circular mapping catheter (Lasso™; Biosense Webster)&#xD;
      introduced through a second transseptal puncture. Cryoablations will be applied for 5 minutes&#xD;
      each. Premature terminations will be allowed at the physician's discretion but should be&#xD;
      avoided to allow for detection of late pulmonary vein isolation during cryoenergy&#xD;
      application. Cryoballoon catheter manipulations (e.g., pull down maneuver) may be performed&#xD;
      during energy application. During ablation of septal pulmonary veins, electrical phrenic&#xD;
      nerve stimulation will be performed to exclude phrenic nerve palsy. If additional single&#xD;
      point ablations are required to achieve electrical isolation of pulmonary veins, a linear&#xD;
      cryocatheter (Freezor™ Max; Medtronic) will be used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility, defined as successful pulmonary vein isolation using the novel circular mapping catheter with the cryoballoon.</measure>
    <time_frame>Participants will be followed for the duration of the ablation procedure, an expected average of 1-3 hours.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from beginning of the freeze to conduction blockade (&quot;time to effect&quot;).</measure>
    <time_frame>Participants will be followed for the duration of the ablation procedure, an expected average of 1-3 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events.</measure>
    <time_frame>Participants will be followed for the duration of the ablation procedure, an expected average of 1-3 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time.</measure>
    <time_frame>Participants will be followed for the duration of the ablation procedure, an expected average of 1-3 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall fluoroscopy time and dose.</measure>
    <time_frame>Participants will be followed for the duration of the ablation procedure, an expected average of 1-3 hours.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Paroxysmal atrial fibrillation.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoballoon ablation.</intervention_name>
    <description>Cryoballoon ablation using a novel circular mapping catheter.</description>
    <arm_group_label>Paroxysmal atrial fibrillation.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented paroxysmal atrial fibrillation&#xD;
&#xD;
          -  ≥18 and ≤75 years of age&#xD;
&#xD;
          -  Failure of one or more antiarrhythmic drugs&#xD;
&#xD;
          -  Referral for a pulmonary vein isolation catheter ablation procedure to treat atrial&#xD;
             fibrillation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous ablation of atrial fibrillation&#xD;
&#xD;
          -  Documented left atrial thrombus&#xD;
&#xD;
          -  Irregular pulmonary vein anatomy according to transesophageal echocardiography&#xD;
&#xD;
          -  Atrial fibrillation secondary to reversible cause&#xD;
&#xD;
          -  Amiodarone therapy in the previous 6 months&#xD;
&#xD;
          -  Cardiac surgery within the prior 6 months&#xD;
&#xD;
          -  Myocardial infarction within the previous 2 months&#xD;
&#xD;
          -  Ejection fraction &lt; 40%&#xD;
&#xD;
          -  NYHA class III or IV&#xD;
&#xD;
          -  Moderate to severe valvular heart disease&#xD;
&#xD;
          -  Previous valve replacement&#xD;
&#xD;
          -  Pacemaker or implantable cardioverter defibrillator placement in the prior 3 months&#xD;
&#xD;
          -  History of stroke or TIA within the previous 12 months&#xD;
&#xD;
          -  Left atrial size ≥ 50 mm&#xD;
&#xD;
          -  Contraindication for anticoagulation medication&#xD;
&#xD;
          -  Life expectancy of less than 12 months&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dierk Thomas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, University of Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>September 30, 2011</study_first_submitted>
  <study_first_submitted_qc>October 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2011</study_first_posted>
  <last_update_submitted>July 24, 2013</last_update_submitted>
  <last_update_submitted_qc>July 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Dierk Thomas, M.D.</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>catheter ablation</keyword>
  <keyword>circular mapping catheter</keyword>
  <keyword>cryoballoon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

